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Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder affecting the central nervous system, which is also 
associated with progressive loss of memory and cognition. The development of numerous structural classes of compounds 
with different pharmacological profile could be an evolving, promising therapeutic approach for the treatment of AD. 
Thus, providing a symptomatic treatment for this disease are cholinomimetics with the pharmacological profile of Acetyl-
cholinesterase (AChE) inhibitors. In view of this, we have synthesized novel 3-aryl-N-methyl-1,2,5,6-tetrahydropyridine 
derivatives 5a-k by Suzuki coupling and screened the efficacy of these derivatives for their AChE inhibitor activity. 
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1. INTRODUCTION 
  Alzheimer's disease (AD) is an irreversible, progressive 
neurodegenerative disorder that occurs gradually and results 
in memory loss, unusual behavior, personality changes and a 
decline in thinking abilities [1]. Taking into account the in-
crease in life expectancy, the fact that the incidence of AD 
increases with advancing age and the devastating effects of 
this illness, nowadays AD represents a major public health 
problem and will presumably be the most important pathol-
ogy of the 21
st century in the developed countries. Efforts 
have been made in the last two decades in order to determine 
the etiopathogenesis of AD and to carry out its early diagno-
sis and therapeutic control [2, 3]. Survival disease is variable 
in patients with AD and they usually die of infections, with 
death occurring approximately 10 years after the onset of 
symptoms. Thus, AD is the third largest cause of death in the 
western world after cardiovascular diseases and cancer. As a 
consequence, potentiation of central cholinergic action has 
become an effective approach for the palliative treatment of 
mild to moderate cases of AD [4]. Several therapeutic strate-
gies have been explored to enhance cholinergic neurotrans-
mission in order to alleviate some of the symptoms of AD. 
These include the use of Acetylcholinesterase inhibitors, the 
administration of acetylcholine precursors, the investigation 
of acetylcholine releasers and direct acetylcholine receptor 
agonists [5]. Among these strategies, inhibition of AChE has 
proven to be the most successful means to balance the cho-
linergic deficit and to stabilize the symptoms [6]. Two main 
strategies can be adapted in the treatment of AD, alleviating 
the cognitive deficits and slowing down degenerative proc-
ess. Current therapy comes under the first approach [7]. To 
date, the cholinesterase inhibitors have been shown to im-
prove some aspects of cognitive performance, however, effi-
cacy has been poor and side effects are problematic [8-10]. A 
variety of compounds particularly cholinesterase inhibitors, 
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were used in an attempt to increase cholinergic activity [11, 
12]. Physo-stigmine (1,2,3,3a,8,8a-hexahydro-1, 3a,8-trimet-
hyl-,methyl-carbamate(ester),(3aS,8aR)-pyrrolo(2,3- b)indol-5-
ol), was one of the earlier acetylcholinesterase (AChE) in-
hibitors studied, produced modest improvements in cogni-
tion, but its use was limited because of frequent dosing 
regimen and severe adverse reactions [13-15]. The first 
available treatment for AD was THA (1,2,3,4-tetrahydro-9-
aminoacridine), which demonstrated moderate but signifi-
cant efficacy [16]. Arecoline (Methyl 1,2,5,6-tetra-hydro-1-
methylpyridine-3-carboxylate) is a naturally occurring alka-
loid with cholinergic properties as a tertiary amine. This 
muscarinic agonist has strong lipophilic properties and can 
easily cross the blood-brain barrier after systemic admini-
stration [17]. Many experimental studies in animals [18, 19] 
as well as few clinical studies in demented patients and nor-
mal volunteers [20, 21] have demonstrated the ability of 
arecoline to prevent or to reduce memory deficit. Due to 
rapid  in vivo hydrolysis of the ester functional group, 
arecoline has an extremely short half life and negligible ac-
tivity after oral administration [22, 23]. Based on the knowl-
edge acquired from the basic studies of several known 
arecoline derivatives about the structural requirements for 
potent AChE inhibitors, a series of N-methyl tetrahydropyri-
dine-3 derivatives were been synthesized and screened for 
their efficacy as AChE inhibitors. 
2. RESULTS AND DISCUSSION 
2.1. Chemistry 
  The preparation of novel 3-aryl-N-methyl-1,2,5,6-
tetrahydropyridine derivatives 5a-k is  summarized in 
Scheme 1, via Suzuki coupling by using commercially avail-
able 3-bromopyridine as starting material. The synthesis in-
volves three steps; the first step involves the Suzuki cou-
pling, where mixture of 3-bromopyridine and substituted aryl 
boronic acids in toluene: H2O (1: 1) was refluxed overnight 
using bis(triphenylphosphine) palladium (II) dichloride as a 
catalyst in the presence of the mild base K2CO3. The pres-
ence of aromatic proton peaks at 6.9-7.8 ppm in the 
1H NMR 
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second step is the N-methylation using Methyl iodide in ace-
tone as a solvent at room temperature and the formation of 
the derivatives 4a-k was confirmed by the presence of sin-
glet methyl peak at 2.51 ppm. The third step is the reduction 
of the N-substituted pyridine 5a-k using NaBH4 in Methanol, 
the presence of a triplet of an olefinic proton at 6.2-6.35 ppm 
and also the multiplets for aliphatic proton at 2.4-3.3 ppm in 
the 
1H NMR spectra, confirming the partial reduction of the 
pyridine ring. All the synthesized compounds 5a-k obtained 
in good yield ranged from 77-92% with high purity. The 
chemical structures, physical data and purity of the deriva-
tives are shown in Table 1. 
Table 1.  Chemical Structure, Yield and Purity of the Synthe-
sized Compounds 5a-k 
 
Compound  R  Yield (%)  Purity (%) 
 5a  4-CF3    85   97.1 
5b  4-CN   80  96.4 
5c  3-COCH3 77  98.5 
5d  4-Cl 88  96.3 
5e  4-OCH3 90  98.2 
5f  2,6-dichloro   83  99.0 
5g  4-C6H5O 85  96.4 
5h  2-F-4-phenyl 89  97.5 
5i  3-OH 86  98.5 
5j  3-OC2H5 82  97.4 
5k  2-F, 3-Cl  83  98.3 
2.2. AChE activity 
  The inhibitory activities of the novel synthesized com-
pounds against AChE were studied using the method of Ell-
man et al. [24]. Determination of the rate of hydrolysis of 
Acetylthiocholine (ATCh) in the presence of inhibitors 
against different sources such as electric eel AChE, human 
serum AChE and rat brain homogenate AChE is shown in 
Figs. (1-3), respectively. The comparative inhibitory activi-
ties of 5a-k are tabulated in Table 2. 
0
20
40
60
80
100
120
0 100 200 300 400 500
Inhibitory concentration (nM)
A
c
t
i
v
i
t
y
 
 
r
e
m
a
i
n
i
n
g
 
(
%
)
5a
5b
5h
5k
Nt
 
Fig. (1). Inhibition of electric eel AChE by tetrahydropyridine de-
rivatives. 
 
0
20
40
60
80
100
120
0 100 200 300 400 500
Inhibitory concentration (nM)
A
c
t
i
v
i
t
y
 
 
r
e
m
a
i
n
i
n
g
 
(
%
)
5a
5b
5h
5k
Nt
 
Fig. (2). Inhibition of human serum AChE by tetrahydropyridine 
derivatives. 
  Activities of the synthesized compounds were compared 
with the inhibitory activity shown by the known standard 
inhibitor Neostigmine [25]. Activity was 50% at a dose of 
50.2, 63.4, 122.0 and 176.8 nM for compounds 5a, 5b, 5h 
and 5k respectively. Compounds 5d, 5f, 5g and 5j showed 
less inhibitory activity while compounds 5c, 5e and 5i 
showed no inhibition. The pharmacological conclusion was 
that, trifluoro methyl phenyl ring in compound 5a ( IC50 
=49.5, 52.1, 50.2) effectively blocked the enzyme compared 
to the rest of the derivatives studied. The 4-Cyano phenyl 
ring in 5b (IC50 =64.0, 68.0, 63.6), 2-fluoro-4-biphenyl ring 
Scheme 1. 
N
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i)   [(C6H5)P]2PdCl2, K2CO3, toluene:H2O(1:1), reflux under N2, 12-14 hr
ii)  CH3I, acetone, r.t, 3-4 hr
iii)  NaBH4, methanol, r.t, 3-4 hr
Reagents and conditions:
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in  5h  (IC50 = 118.0, 115.6, 122.6) and 2-fluoro-3-chloro-
phenyl ring in 5k  (IC50 = 182.3, 170.0, 176.8) derivatives 
were also effective in blocking the AChE enzyme activity of 
electric eel, human serum and rat brain homogenate, respec-
tively, which led to the suggestion that compound 5a was 
considered as a potent AChE inhibitor. 
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Fig. (3). Inhibition of rat brain homogenate AChE by tetrahydro-
pyridine derivatives. 
  Among the synthesized molecules, compounds 5a and 5b 
showed good AChE inhibition when compared to the other 
molecules with Neostigmine. This is probably due to the 
presence of electron withdrawing group trifluoromethyl   
(-CF3) in 5a and cyano (-CN) in 5b. From the results ob-
tained, it was revealed that the electron withdrawing sub-
stituent on phenyl ring increases the inhibition, as observed 
from the derivatives 5a, 5b, 5k, 5h and 5f. The presence of 
electron donating groups on phenyl ring (5e, 5i and 5j) had 
no AChE inhibition. The aromatic fluoro substituent is 
slightly smaller than hydrogen in terms of molecular refrac-
tivity (MR) being 0.09 versus 0.10. Therefore, the fluoro 
substituent acts as a potent inhibitor. The molecules synthe-
sized herein were expected to enter the central nervous sys-
tem (CNS) because of the structural similarity with 
Arecoline. The smaller the substituent, it raised greater ex-
pectations of a more favorable activity at tetrahydropyridine-
3 site of the molecule. From the SAR, it was observed that 
the  N-methyl tetrahydropyridine-3 derivatives with 
trifluoromethyl (5a) and cyano substituents (5b) showed 
better activity than the other derivatives mentioned. The re-
sults of reversing amnesic effect of scopolamine induced 
memory loss in passive avoidance step-down task paradigm 
in rat [24] are shown in Table 3. Compound 5a, 5b and 5h 
minimized the number of mistakes done to 13, 15 and 18 
from 34 mistakes done by scopolamine induced memory 
loss. Our findings revealed that compounds 5a, 5b and 5h 
improved scopolamine induced impairment of memory reg-
istration in passive avoidance behavior in mice. It is well 
known that the cholinergic system plays an important role in 
learning and memory [26] and there is evidence from both 
animal and human studies indicating that learning and mem-
ory can be modified by drugs that affect central cholinergic 
function [27]. In light of these findings, our results suggest 
that the antiamnesic effect of 5a, 5b and 5h on scopolamine-
induced impairment of learning and memory may be related 
to modification of cholinergic neuronal systems. The results 
of compounds showed that in vivo and in vitro results are 
comparable. It can be concluded from this study that for ef-
fective binding and blocking of the AChE activity, the mole-
cule needs to bind with peripheral and active site of the en-
zyme and some N-methyl tetrahydropyridine-3 derivatives 
with substituents such as fluoro, cyano or biphenyl that may 
bind to the active site. The substituents like Cl, OH, OCH3 
and OC2H5 containing aromatic rings bind to peripheral site 
of the enzyme. The structures of potent AChE inhibitors are 
shown in Fig. (4). 
3. CONCLUSION 
 Derivatives  of  N-methyl tetrahydropyridine-3 having 
different substituents in the aryl residue were tested for their 
activity for the substrate acetylcholine iodide. The order of 
Table  2.  Comparative Inhibitory Activities Shown by the Tetrahydropyridine Derivatives 5a-k Against AChE from Different 
Sources 
 
Compound  Electric eel AChE, IC50 nM  Human Serum AChE, IC50 nM  Rat brain Homogenate AChE, IC50 nM 
5a 49.5  52  51.6 
5b 64.0  68.0  63.6 
5c  NI NI  NI 
5d  806 784  827 
5e  NI 2876  NI 
5f  678 729  704 
5g  1234.8 1350.4  1289.2 
5h  118 115.6  122.6 
5i  NI NI  NI 
5j  1234.1 1224.6  1238 
5k  182.3 170  176.8 
Neostigmine  36.5 39.2  38.4 
Values are means of three determinations, the ranges of which were less than 5% of the mean in all cases. 
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potency is 5a>5b>5h>5k. The other compounds screened 
failed to elicit any inhibition of acetyl cholinesterase from 
electric eel, human serum rat brain homogenate. The mole-
cules synthesized herein can be expected to enter the central 
nervous system (CNS) because of the structural similarity 
with Arecoline. Two of the analogs synthesized 5a and 5b 
have AChE inhibitory activity and may provide new leads in 
the search for effective AChE inhibitory agents. Therefore, it 
has been summarized that substituting heterocyclic ring to 
the aromatic ring on N-methyl tetrahydropyridine-3 deriva-
tives may increase the efficacy of AChE inhibitory activity 
and to achieve this, the work is under progress. 
N
CF3
N
CN
N
C
O
OCH3
5a 5b Arecoline  
Fig. (4). Structures of potent AChE inhibitors and Arecoline. 
4. EXPERIMENTAL 
  Infrared (IR) spectra were recorded using a Jasco FTIR-
4100 series. Nuclear magnetic resonance (
1H-NMR) spectra 
were recorded on Shimadzu AMX 400-Bruker, 400MHz 
spectrometer using D6 DMSO as a solvent and TMS as an 
internal standard (chemical shift in  ppm). Mass and purity 
were recorded on a LC- MSD-Trap-XCT. Elemental 
(CHNS) analysis was obtained on Vario EL III Elemental 
Analyzer. Silica gel column chromatography was performed 
using Merck 7734 silica gel (60-120 mesh) and Merck made 
TLC plates. 
4.1. General Procedures for the Synthesis of 3-Aryl pyri-
dines 3a-k 
  To a solution of 3-bromopyridine (1.0 equiv) in toluene 
and H2O (1: 1), K2CO3 (3.0 equiv) was added and stirred for 
10 min at room temperature under N2, followed by the addi-
tion of (Ph3P)2PdCl2 (0.1 equiv) and substituted aryl boronic 
acids (1.1 equiv). The mixture was refluxed overnight (Jin-
Heng Tetrahedron Lett 2006) [28]. The progress of the reac-
tion was monitored by TLC. After completion of the reac-
tion, the mixture was filtered through celite to remove the 
palladium particles and the filtrate was evaporated under 
reduced pressure. The residue was taken in H2O, extracted 
with Ethyl acetate and dried over anhydrous Na2SO4. Pure 
compounds been obtained by column chromatography using 
Hexane/Ethyl acetate (8: 2) as an eluent and the compounds 
were characterized by 
1H-NMR spectroscopy and LCMS. 
4.2. General Procedures for the Synthesis of N-methyl-
pyridine-3 Derivatives 4a-k 
 The  compounds  3a-k were taken in the 10-fold volume 
of acetone, then methyl iodide (4.0 equiv) was added and the 
mixture stirred for 3-4 hr. After completion of the reaction, 
the reaction was monitored by TLC and the solvent was 
evaporated under reduced pressure. A yellow pyridinum salt 
4a-k was obtained and taken for reduction [29]. 
4.3. General Procedures for the Synthesis 3-aryl-N-
methyl-1,2,5,6-tetrahydropyridine Derivatives 5a-k 
 The  compounds  4a-k were taken in MeOH, NaBH4 (3.0 
equiv) was added and the mixture stirred at rt for 3-4 hr. Af-
ter completion of the reaction, the reaction was monitored by 
TLC. H2O was added and extracted with Ethyl acetate. Pure 
compounds were obtained as oils after evaporation of the 
solvent under reduced pressure. All the compounds were 
characterized by 
1H-NMR, LC/MS, FTIR and CHN analysis. 
4.3.1. Synthesis of 3-[4-(trifluoromethyl)phenyl]-1,2,5,6-
tetrahydro-1-methylpyridine 5a 
  Obtained from 1-methyl-3-(4-trifluoromethyl-phenyl) 
pyridinium salt (4a), (0.5 g, 1.36 mmol), NaBH4 (0.257 g, 
6.80 mmol). Oily liquid (0.278 g, 85%). 
1H-NMR (CDCl3, 
Table 3.  Study of Antiamnesic Effect of Tetrahydropyridine Derivatives Against Scopolamine Induced Memory Loss 
 
Basal Latecy (s) of Rat to Reach Shock- Free Zone (SFZ)  Memory Parameters 
S. No.  Experimental  
Groups 
Treatment (Dose)  
mg/kg ip  I  II  III  Latency (s)  No. of Mistakes 
1 Control  groups  -  19  4  0.9  1  8 
2 Scopolamine  treated  0.4 35  10  8  4  34 
3  5a treated groups  0.1  22 8 4  3  13 
4  5b  0.1  25 9 5  4  15 
5  5c  0.1  34 9 8  4  32 
6  5d  0.1  30 8 7  4  30 
7  5e  0.1  33 9 8  4  33 
8  5f  0.1  30 8 6  3  30 
9  5g  0.1  30 8 7  4  30 
10  5h  0.1  26 6 3  3  18 
11  5i  0.1  34 9 8  4  33 
12  5j  0.1  30 8 7  4  30 
13  5k  0.1  28 6 5  3  20 8    The Open Medicinal Chemistry Journal, 2007, Volume 1  Benaka Prasad et al. 
400MHz) : 7.74 (d, 2H, Ar-H), 7.45 (d, 2H, Ar-H), 6.35 (t, 
1H, -CH), 3.33 (s, 2H, -CH), 2.62 (t, 2H, -CH), 2.50 (s, 3H,  
-CH), 2.41 (m, 2H, -CH2). IR (KBr, cm
-1): 3045, 2931, 2615, 
1616, 1465, 1173. MS  (ESI)  m/z: 242.15(M+H
+). Anal. 
calc.for C13H14F3N (in %): C-64.72, H-5.85, N-5.81. Found 
C-64.68, H-5.81, N-5.78. 
4.3.2. Synthesis of 3-(4-cyanophenyl)-1,2,5,6-tetrahydro-
1-methylpyridine 5b 
  Obtained from 3-(4-cyano-phenyl)-1-methyl-pyridinum 
salt (4b), (0.5 g, 1.55 mmol), NaBH4 (0.293 g, 7.75 mmol). 
The product obtained was oily liquid (0.245 g, 80%). 
1H-
NMR (CDCl3, 400MHz) : 7.72(d, 2H, Ar-H) 7.49 (d, 2H, 
Ar-H), 6.35 (t, 1H, -CH), 3.33 (s, 2H, -CH), 2.62 (t, 2H,   
-CH), 2.53 (s, 3H, -CH), 2.41 (m, 2H, -CH2). IR (KBr,   
cm
-1): 3025, 2945, 2630, 2223, 1630. MS  (ESI)  m/z: 
199.10(M+H
+). Anal. Calc. for C13H14N2 (in %): C-78.75, H-
7.12, N-14.13. Found C-78.72, H-7.09, N-14.00. 
4.3.3. Synthesis of 3-(3-acetylphenyl)-1,2,5,6-tetrahydro-
1-methylpyridin 5c 
  Obtained from 3-(3-acetyl-phenyl)-1-methyl-pyridinium 
salt (4c), (0.5 g, 1.07 mmol), NaBH4 (0.202 g, 5.36 mmol). 
The product obtained was oily liquid (0.178 g, 77%). 
1H-
NMR (CDCl3, 400MHz) : 7.4 (s, 1H, Ar-H), 7.42 (d, 1H, 
Ar-H), 7.22 (m, 2H, Ar-H) 6.34 (t, 1H, -CH), 3.33 (s, 2H,  
-CH), 2.62 (t, 2H, -CH), 2.60 (s, 3H, -COCH3), 2.52 (s, 3H,  
-CH), 2.41 (m, 2H, -CH2). IR (KBr, cm
-1): 3028, 2940, 2618, 
1670, 1628. MS (ESI) m/z: 217.26(M+H
+). Anal. Calc. for 
C14H17NO (in %): C-78.10, H-7.96, N-6.51. Found C-78.06, 
H-7.92, N-6.48. 
4.3.4. Synthesis of 3-(4-chlorophenyl)-1,2,5,6-tetrahydro-
1-methylpyridine 5d 
  Obtained from 3-(4-chloro-phenyl)-1-methyl-pyridinium 
salt (4d), (0.5 g, 1.51 mmol), NaBH4 (0.28 g, 7.55 mmol). 
The product obtained was oily liquid (0.275 g, 88%). 
1H-
NMR (CDCl3, 400MHz) : 7.32 (d, 2H, Ar-H) 7.22 (d, 2H, 
Ar-H), 6.33 (t, 1H, -CH), 3.31 (s, 2H, -CH), 2.62 (t, 2H,   
-CH), 2.54 (s, 3H, -CH), 2.40 (m, 2H, -CH2). IR (KBr,   
cm
-1): 3018, 2928, 2535, 1646, 718. MS  (ESI)  m/z: 
208.9(M+H
+). Anal. Calc. for C12H14ClN (in %): C-69.39, 
H-6.79, N-6.74. Found C-69.35, H-6.76, N-6.70. 
4.3.5. Synthesis of 3-(4-methoxyphenyl)-1,2,5,6-tetrahydro-
1-methylpyridine 5e 
  Obtained from 3-(4-methoxy-phenyl)-1-methyl-pyridini-
um salt  (4e),  (0.5 g, 1.52 mmol), NaBH4 (0.28 g, 7.64 
mmol). The product obtained was oily liquid (0.279 g, 90%). 
1,2,3, 6-tetrahydro-5-(4-methoxyphenyl)-1-methylpyridine. 
1H-NMR (CDCl3, 400MHz) : 7.25 (d, 2H, Ar-H), 7.00 (d, 
2H, Ar-H), 6.24 (t, 1H, -CH), 3.83 (s, 3H, -OCH3), 3.33 (s, 
2H, -CH), 2.63 (t, 2H, -CH), 2.60 (s, 3H, -CH), 2.44 (m, 2H, 
-CH). IR (KBr, cm
-1): 3012, 2931, 2512, 1643, 1193. MS 
(ESI) m/z: 204.3(M+H
+). Anal. Calc. for C13H17NO (in %): 
C-76.81, H-8.43, N-6.89. Found C-76.78, H-8.39, N-6.85. 
4.3.6. Synthesis of 3-(2,6-dichlorophenyl)-1,2,5,6-tetrahydro- 
1-methylpyridine 5f 
  Obtained from 3-(2,6-dichloro-phenyl)-1-methyl-pyridi-
niumsalt  (4f),  (0.5 g, 1.36 mmol), NaBH4 (0.258 g, 6.82 
mmol). The product obtained was oily liquid (0.273 g, 
83%).
1H NMR (CDCl3, 400MHz) : 7.64 (d, 2H, Ar-H) 7.52 
(t, 1H, Ar-H), 6.26 (t, 1H, -CH), 3.4 (s, 2H, -CH), 2.66 (t, 
2H, -CH), 2.54 (s, 3H, -CH), 2.44 (m, 2H, -CH). IR (KBr, 
cm
-1): 3027, 2965, 2532, 1622, 707. MS  (ESI)  m/z: 
242.1(M+H
+). Anal. Calc. for C12H13Cl2N (in %): C-59.92, 
H-5.41, N-5.78. Found C-59.89, H-5.38, N-5.75. 
4.3.7. Synthesis of 3-(4-phenoxyphenyl)-1,2,5,6-tetrahydro- 
1-methylpyridine 5g 
  Obtained from 3-(4-phenoxyphenyl)-1-methyl-pyridi-
nium salt (4g), (0.5 g, 1.28 mmol), NaBH4 (0.242 g, 6.42 
mmol). The product obtained was oily liquid (0.289 g, 85%). 
1H NMR (CDCl3, 400MHz) : 7.45 (d, 4H, Ar-H), 7.25-7.35 
(m, 5H, Ar-H), 6.28 (t, 1H, -CH), 3.35 (s, 2H, -CH), 2.62 (t, 
2H, -CH), 2.52 (s, 3H, -CH), 2.43 (m, 2H, -CH). IR (KBr, 
cm
-1): 3126, 2943, 2528, 1642, 1370. MS  (ESI)  m/z: 
266.10(M+H
+). Anal. Calc. for C18H19NO (in %): C-81.47, 
H-7.22, N-5.28. Found C-81.44, H-7.18, N-5.25. 
4.3.8. Synthesis of 3-(2-fluoro-biphenyl-4-yl)-1-methyl-
1,2,5,6-tetrahydropyridine 5h 
  Obtained from 3-(2-fluoro-biphenyl-4-yl)-1-methyl-pyri-
dinium salt (4h), (0.5 g, 1.27mmol), NaBH4 (0.241 g, 6.39 
mmol). The product obtained was oily liquid (0.303 g, 89%). 
1H NMR (CDCl3, 400MHz) : 7.7 (d, 1H, Ar-H), 7.40 (d, 
2H, Ar-H), 7.25-7.35 (m, 5H, Ar-H), 6.34 (t, 1H, -CH), 3.24 
(s, 2H, -CH), 2.61 (t, 2H, -CH), 2.52 (s, 3H, -CH), 2.41 (m, 
2H, -CH). IR (KBr, cm
-1): 3140, 2934, 2538, 1634, 1228. 
MS (ESI) m/z: 268.20(M+H
+). Anal. Calcd. for C18H18FN (in 
%): C-80.87, H-6.79, N-5.24. Found C-80.84, H-6.75, N-
5.22. 
4.3.9. Synthesis of 3-(phenol-3-yl) 1,2,5,6-tetrahydro-1-
methylpyridine 5i 
  Obtained from 3-(phenol-3-yl) -1-methyl-pyridinium salt 
(4i), (0.5 g, 1.60 mmol), NaBH4 (0.302 g, 8.0 mmol). The 
product obtained was oily liquid (0.259 g, 86%). 
1H NMR 
(CDCl3, 400MHz) : 7.4 (s, 1H, Ar-H), 6.92-7.25 (m, 3H, 
Ar-H), 6.28 (t, 1H, -CH), 3.22 (s, 2H, -CH), 2.58 (t, 2H, -
CH), 2.49 (s, 3H, -CH), 2.44 (m, 2H, -CH). IR (KBr, cm
-1): 
3610, 3148, 2943, 2531, 1627. MS  (ESI)  m/z: 
190.08(M+H
+). Anal. Calc. for C12H15NO (in %): C-79.16, 
H-7.99, N-7.40. Found C-79.95, H-7.96, N-7.37. 
4.3.10. Synthesis of 3-(3-ethoxyphenyl)-1,2,5,6-tetrahydro- 
1-methylpyridine 5j 
  Obtained from 3-(3-ethoxyphenyl) pyridine salt (4j), (0.5 
g, 1.46 mmol), NaBH4 (0.277 g, 7.30 mmol). The product 
obtained was oily liquid (0.260 g, 82%). 
1H NMR (CDCl3, 
400MHz) : 7.38 (s, 1H, Ar-H), 6.89-7.28 (m, 3H, Ar-H), 
6.24 (t, 1H, C-H), 3.5 (q, 2H, -CH2), 3.22 (s, 2H, -CH), 2.58 
(t, 2H, -CH), 2.52 (s, 3H, -CH3), 2.44 (m, 2H, -CH), 1.62 (t, 
3H, -CH3). IR (KBr, cm
-1): 3146, 2965, 2523, 1633. MS (E-
SI) m/z: 218.10(M+H
+). Anal. Calc. for C14H19NO (in %): C-
77.38, H-8.81, N-6.45. Found C-77.35, H-8.78, N-6.42. 
4.3.11. Synthesis of 3-(3-chloro-2-fluoro-phenyl)-1-methyl-
1,2,5,6-tetrahydropyridine 5k 
  Obtained from 3-(3-Chloro-2-fluoro-phenyl)-pyridinum 
salt (4k), (0.5 g, 1.43 mmol), NaBH4 (0.270 g, 7.32 mmol). 
The product obtained was oily liquid (0.0.268 g, 83%). 
1H 
NMR (CDCl3, 400MHz) : 7.45 (d, 1H, Ar-H), 7.27 (d, 1H, Novel 3-Aryl-N- Methyl-1,2,5,6-Tetrahydropyridine Derivatives  The Open Medicinal Chemistry Journal, 2007, Volume 1    9 
Ar-H), 7.12 (t, 1H, Ar-H), 6.29 (t, 1H, -CH), 3.25 (s, 2H, -
CH2), 2.63 (t, 2H, -CH2), 2.58 (s, 3H, -CH3), 2.51 (m, 2H, -
CH2). IR (KBr, cm
-1): 3156, 2536, 1632, 1232, 760. MS (E-
SI) m/z: 227.08(M+H
+). Anal. Calc.for C12H13ClFN (in %): 
C-63.86, H-5.81, N-6.21. Found C-63.85, H-5.79, N-6.19. 
4.4. Biology: In Vitro Cholinesterase Assay 
  The cholinesterase assay was done by using the method 
described by Ellman et al. [30] to determine the in vitro cho-
linesterase activity. The activity was measured by the in-
crease in absorbance at 412nm due to the yellow color pro-
duced from the reaction of thiocholine with the dithiobisni-
trobenzoate ion. Rat brain AChE was obtained from the 
brain of wistar rat by homogenizing under Teflon blender for 
10 minutes in 0.1M KH2PO4 buffer pH 8. A stock solution of 
Enzyme in 0.1M KH2PO4 buffer (pH 8.0) was kept frozen. 
For each assay, 300g of enzyme was used; acetylthiocho-
line iodide was prepared daily using 0.1M KH2PO4 buffer 
(pH 7.0). A 0.01M solution of DTNB was prepared in 0.1M 
KH2PO4buffer (pH 7.0). Crude human AChE was obtained 
by mixing 9 ml of fresh blood (collected from healthy volun-
teer by vein puncture) with 1ml of 3.8 % (w/v) trisodium 
citrate and centrifuging at 3000rpm at 0
0C for 20min. The 
supernatant was used as a source of AChE. Electric eel 
AChE was obtained from sigma laboratory and similar pro-
cedure was employed for the assay as that of rat brain AChE. 
Experimental Condition and Kinetics 
  Enzyme activity was measured using Shimadzu Spectro-
photometer. The assay medium contained phosphate buffer, 
pH 8.0 (2.6 ml), DTNB (0.1 ml), 5 l of enzyme, 20 l of 
0.075 M substrate. The activity was determined by measur-
ing the increase in absorbance at 412 nm at 1 minute interval 
for 10 minutes at 37
0C. In dose dependent  inhibition  stud-
ies, the substrate was added to the assay medium containing 
enzyme, buffer and DTNB with inhibitor after 10 minutes of 
incubation time. Calculations were performed according to 
the method of the equation in Ellman et al. All experiments 
were carried out in triplicate and the mean values are re-
ported here. The relative activity was expressed as percent-
age ratio of enzyme activity in the absence of inhibitor. 
Protein Estimation 
  Protein content was determined by Lowry method [31] 
using bovine serum albumin as standard. 
IC50 Determination 
  AChE inhibitor Neostigmine (a reversible cholinesterase 
inhibitor), was used in the concentration range 10 to 90 nM 
to inhibit the AChE of electric eel, human serum, and rat 
brain homogenate [32]. Inhibition by tetrahydro pyridine 
derivatives was studied in the presence of different concen-
trations of compounds and the percentage inhibition of en-
zyme activity was calculated. The inhibition of AChE by 
tetrahydro pyridine derivatives was analyzed with values 
obtained in comparison to that of Neostigmine. Antiamnesic 
effect was carried out for synthesized tetrahydro pyridine 
derivatives against scopolamine induced memory loss using 
passive avoidance step-down task paradigm in rats according 
to the method of Sharma and Kulkarni [33, 34]. 
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